Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 338 clinical trials
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.

EGFR
lung cancer
solid tumor
epidermal growth factor receptor
growth factor
  • 0 views
  • 16 Feb, 2024
  • 39 locations
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.

monoclonal antibodies
lung cancer
stage ia1 lung cancer ajcc v8
kidney function test
small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 22 locations
Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

The goal of part 1 of this trial is to find the highest tolerable dose of alisertib or sapanisertib in combination with osimertinib that can be given to patients with EGFR mutated non-small cell lung cancer. The goal of part 2 of this trial is to learn if the dose …

EGFR
serum glucose
lung cancer
lung carcinoma
hemoglobin a1c
  • 0 views
  • 16 Feb, 2024
  • 1 location
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Chemotherapy-nave patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung cancer patients will be selected. Patients enrolled in the study will receive brigatinib 90mg for the first 7 days (D 1-7 at cycle 1) and then 180mg daily thereafter for QW4 cycles of duration (28 days …

chemo-radiotherapy
lung cancer
bone metastases
lipase
stroke
  • 0 views
  • 16 Feb, 2024
  • 15 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

EGFR
adjuvant therapy
NTRK
ros1
carboplatin
  • 0 views
  • 16 Feb, 2024
  • 28 locations
Investigation of an Abdominal Compression Device

This study is applicable to patients undergoing lower lung or abdomen stereotactic ablative body radiotherapy (SABR) treatment. The purpose of the ACE 01 study is to identify if, the volume of healthy tissue within the treatment area and therefore subsequent side effects, can be reduced by using a commercially available …

cancer
primary cancer
adrenal
lung cancer
primary malignant neoplasm
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

cancer
peritoneal cancer
fallopian tube
non-small cell lung cancer
ovarian cancer
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying …

stage iii non-small cell lung cancer
lung cancer
urine test
pet/ct scan
small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Evaluation of GLR2007 for Advanced Solid Tumors

This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.

EGFR
immune checkpoint inhibitor
contrast-enhanced magnetic resonance imaging
solid tumor
NTRK
  • 0 views
  • 16 Feb, 2024
  • 4 locations
SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions

Prospective phase I study to evaluate the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation. Dose limiting toxicity will be pneumonitis G3. The potential advantage of the dose escalation planned in this study is the delivery of an ablative dose to radically treat patients with inoperable local relapse, without …

cancer
tumor recurrence
non-small cell lung cancer
pulmonary metastasis
lung cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location